MAMATHA CHIVUKULA,MD,FASCP Profile
MAMATHA CHIVUKULA,MD,FASCP

@ChivukulaMd

Followers
219
Following
332
Media
45
Statuses
369

“Making life better for others than yourself “ Passions - my work and my running

Burlingame, CA
Joined February 2017
Don't wanna be here? Send us removal request.
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
1 year
Interesting data ..
@EricTopol
Eric Topol
1 year
Just out @Nature The 1st whole-slide digital pathology #AI foundation model pre-trained on large-scale real-world data, from over 1.3 billion images, 30,000 patients https://t.co/K3mKkHPdtu @hoifungpoon @HanwenXu6 @Microsoft @UW @naotous @MSFTResearch
0
0
0
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
2 years
Coco Gauff❤️@usopen
0
0
3
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
2 years
Vamos @carlos Alcaraz @Wimbledon 🏆👏🏼🎉🎊at 20 yrs
0
0
0
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
Thank you ; muchas Gracias 🙏🏽to all Medical Laboratory Professionals @rex_mls @ASCP_Chicago #National lab week 🔬🧪🧫
0
0
1
@DrBuiPathology
Dr. Bui Pathologist🌼
3 years
There are differences in QIA approach. Some analyze areas of interest. Some analyze the whole tumor area. Some algorithm trained to adjust the HER2 FISH data.
@ASCP_Chicago
ASCP
3 years
Q7: What can we learn from the quantitative image analysis (QIA) studies evaluating HER2 interpretation? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
2
2
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
#her2low CAP guidelines on QIA of HER2 IHC were published in 2019
@ASCP_Chicago
ASCP
3 years
Q7: What can we learn from the quantitative image analysis (QIA) studies evaluating HER2 interpretation? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
1
0
@Baskotacytopath
Swikrity U Baskota,MD, FCAP,FASCP
3 years
@ASCP_Chicago @DrBuiPathology @ChivukulaMd @KhouryThaer A7: Since interobserver variability still occurs, QIA offers an objective and reproducible scoring method #HER2low #PathTwitter #BreastPath
0
3
3
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
#her2low sTudies of QIA have shown reduced equivocal cases of HER2
@Baskotacytopath
Swikrity U Baskota,MD, FCAP,FASCP
3 years
@ASCP_Chicago @DrBuiPathology @ChivukulaMd @KhouryThaer A7: Since interobserver variability still occurs, QIA offers an objective and reproducible scoring method #HER2low #PathTwitter #BreastPath
0
1
1
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
#her2low micro- papillary carcinoma retraction can be over scored by HER2 IHC
0
3
4
@Baskotacytopath
Swikrity U Baskota,MD, FCAP,FASCP
3 years
A2: Future HER2 evaluation may include RNA-based methods such as RT-qPCR #HER2low #PathTwitter #BreastPath
@ASCP_Chicago
ASCP
3 years
Q2: What were some highlights from the recent review article “Emerging Landscape of Targeted Therapy of Breast Cancers with Low HER2 Protein Expression”? https://t.co/aj6osbCwsQ #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
1
3
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
#HER2low Daisy trail results presented at SABCS2022 and investigators found T-Dxd has clinically meaningful activity in HER2 positive, HER2low and HER2 zero advanced breast cancer,#breast path
@ASCP_Chicago
ASCP
3 years
Q6: What are some of the ongoing HER2-low breast cancer trials for patients? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
1
2
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
#her2low 4B5
@DrBuiPathology
Dr. Bui Pathologist🌼
3 years
A4. We did a survey study to identify the most commonly used antibodies, 4B5 came on top, which is the only FDA approved companion diagnostic indicated to identify HER2-low status in patients with metastatic breast cancer. #HER2low #PathTwitter #BreastPath
0
2
2
@DrBuiPathology
Dr. Bui Pathologist🌼
3 years
A4. We did a survey study to identify the most commonly used antibodies, 4B5 came on top, which is the only FDA approved companion diagnostic indicated to identify HER2-low status in patients with metastatic breast cancer. #HER2low #PathTwitter #BreastPath
@ASCP_Chicago
ASCP
3 years
Q4: Which HER2 antibody assay(s) do you use in your lab? What is required to switch to a new assay or to run multiple assays in the lab? How are these assays different? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
2
3
@Baskotacytopath
Swikrity U Baskota,MD, FCAP,FASCP
3 years
A4: Another comparison of HercepTest and Pathway 4B5: more tumors were overscored as IHC 2 + by HercepTest https://t.co/s10PHXQOJ1 #HER2low #PathTwitter #BreastPath
@ASCP_Chicago
ASCP
3 years
Q4: Which HER2 antibody assay(s) do you use in your lab? What is required to switch to a new assay or to run multiple assays in the lab? How are these assays different? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
5
4
@Baskotacytopath
Swikrity U Baskota,MD, FCAP,FASCP
3 years
A4: Recent abstract from AACR about proficiency assessment of HER2-low scoring using different assays https://t.co/VroKbUtvy4 #HER2low #PathTwitter #BreastPath
@ASCP_Chicago
ASCP
3 years
Q4: Which HER2 antibody assay(s) do you use in your lab? What is required to switch to a new assay or to run multiple assays in the lab? How are these assays different? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
5
6
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
Q5: #her2low thin sections may result in false negative results of HER2
@ASCP_Chicago
ASCP
3 years
Q5: How do preanalytic and analytic variables impact the quality of HER2 testing? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
5
4
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
Q4: beware of crush and edge artifacts scoring HER2 by IHC #her2low
@ASCP_Chicago
ASCP
3 years
Q5: How do preanalytic and analytic variables impact the quality of HER2 testing? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
4
4
@ChivukulaMd
MAMATHA CHIVUKULA,MD,FASCP
3 years
Q4: prolonged cold ischemic time can reduce HER2 IHC staining #her2low
@ASCP_Chicago
ASCP
3 years
Q5: How do preanalytic and analytic variables impact the quality of HER2 testing? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
0
2
3
@ASCP_Chicago
ASCP
3 years
Q5: How do preanalytic and analytic variables impact the quality of HER2 testing? #HER2low #PathTwitter #BreastPath @DrBuiPathology @Baskotacytopath @ChivukulaMd @KhouryThaer
4
3
3